Adage Capital Management, L.P.
Adage Capital Management, L.P.'s purchase track record
Adage Capital Management, L.P. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/18/2025 | SLDB | $1.91M | -44.3% | +9.4% | +4.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SLDB Featured in After-Market Movers List. Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.
Transaction History
| PRAX | ▼ Sell | Open Market | 1,661 | $216K | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 487 | $64K | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 308 | $41K | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 19,198 | $2.7M | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 447 | $41K | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 1,363 | $125K | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 27,287 | $2.8M | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 250,000 | $26.1M | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 559 | $56K | 10/16/2025 | View on chart |
| PRAX | ▼ Sell | Open Market | 12,600 | $1.1M | 10/16/2025 | View on chart |
| SLDB | ▲ Buy | Open Market | 252,545 | $1.9M | 2/18/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Praxis Precision Announces Inducement Grants Under Nasdaq Rule
Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.
Praxis Precision Announces Inducement Grants Under Nasdaq Rule. Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.